Literature DB >> 12888452

Regulation of toll-like receptor 2 and 4 gene expression in murine alveolar macrophages.

Katsuhisa Oshikawa1, Yukihiko Sugiyama.   

Abstract

The authors investigated the regulation of toll-like receptor (TLR) TLR2 and TLR4 gene expression in alveolar macrophage (AM) in response to lipopolysaccharide (LPS) or proinflammatory cytokines in vitro. Treatment of a murine AM cell line, MH-S, with LPS, tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta significantly increased TLR2 mRNA expression, whereas TLR4 mRNA expression remained constant. LPS-mediated TLR2 mRNA up-regulation was attenuated by inhibition of p38 kinase (with SB203580) or nuclear factor (NF)-kappaB (with sulfasalazine or SN-50), but not by inhibition of extracellular signal-regulated kinase (with PD98059) or c-Jun N-terminal kinase (with SP600125), suggesting that LPS may induce TLR2 mRNA expression through p38 kinase and NF-kappaB activation. These results indicate that TLR2 expression up-regulated in AM in response to bacterial respiratory infections may render AM responsive to TLR2 ligands, which may accelerate the innate immunity against pathogens in the lung.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12888452     DOI: 10.1080/01902140303756

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  11 in total

1.  Differential host response to LPS variants in amniochorion and the TLR4/MD-2 system in Macaca nemestrina.

Authors:  J Chang; S Jain; D J Carl; L Paolella; R P Darveau; M G Gravett; K M Adams Waldorf
Journal:  Placenta       Date:  2010-09       Impact factor: 3.481

2.  Damage-associated molecular patterns (DAMPs) released after burn are associated with inflammation and monocyte activation.

Authors:  Meenakshi Rani; Susannah E Nicholson; Qiong Zhang; Martin G Schwacha
Journal:  Burns       Date:  2016-10-27       Impact factor: 2.744

3.  Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease.

Authors:  Charles S Berenson; Catherine T Wrona; Lori J Grove; Jane Maloney; Mary Alice Garlipp; Paul K Wallace; Carleton C Stewart; Sanjay Sethi
Journal:  Am J Respir Crit Care Med       Date:  2006-03-30       Impact factor: 21.405

4.  Effects of the TLR2 agonists MALP-2 and Pam3Cys in isolated mouse lungs.

Authors:  Martina Barrenschee; Dennis Lex; Stefan Uhlig
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

5.  Stanniocalcin-1 attenuates ischemic cardiac injury and response of differentiating monocytes/macrophages to inflammatory stimuli.

Authors:  Arezoo Mohammadipoor; Ryang Hwa Lee; Darwin J Prockop; Thomas J Bartosh
Journal:  Transl Res       Date:  2016-07-09       Impact factor: 7.012

6.  Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage-mediated fungal clearance during Pneumocystis pneumonia.

Authors:  Jing Wang; Francis Gigliotti; Samir P Bhagwat; Thaddeus C George; Terry W Wright
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

7.  Characterization of ovine hepatic gene expression profiles in response to Escherichia coli lipopolysaccharide using a bovine cDNA microarray.

Authors:  Honghe Cao; Leah C Kabaroff; Qiumei You; Alexander Rodriguez; Herman J Boermans; Niel A Karrow
Journal:  BMC Vet Res       Date:  2006-11-29       Impact factor: 2.741

8.  Chlamydophila pneumoniae induces expression of toll-like receptor 4 and release of TNF-alpha and MIP-2 via an NF-kappaB pathway in rat type II pneumocytes.

Authors:  Heide Wissel; Christian Schulz; Petra Koehne; Ekkehard Richter; Matthias Maass; Mario Rüdiger
Journal:  Respir Res       Date:  2005-06-03

Review 9.  Alveolar macrophages: plasticity in a tissue-specific context.

Authors:  Tracy Hussell; Thomas J Bell
Journal:  Nat Rev Immunol       Date:  2014-01-21       Impact factor: 53.106

10.  A critical role for MAPK signalling pathways in the transcriptional regulation of toll like receptors.

Authors:  Marylene Y Peroval; Amy C Boyd; John R Young; Adrian L Smith
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.